An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension
Open Access
- 24 September 2022
- journal article
- research article
- Published by Elsevier in Acta Biomaterialia
- Vol. 153, 411-418
Abstract
No abstract availableKeywords
Funding Information
- Carlsbergfondet (CF20-0045)
- Novo Nordisk Fonden (NNF17OC0028070)
This publication has 43 references indexed in Scilit:
- Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albuminJournal of Biological Chemistry, 2017
- Albumin-based drug delivery: harnessing nature to cure diseaseMolecular and Cellular Therapies, 2016
- Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugsJournal of Controlled Release, 2016
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human SubjectsClinical Pharmacokinetics, 2013
- Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptorNature Communications, 2012
- Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineeringProtein Expression and Purification, 2008
- The emerging role of ACE2 in physiology and diseaseThe Journal of Pathology, 2007
- A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9Circulation Research, 2000
- Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.Journal of Clinical Investigation, 1996